Adeno-Associated Virus (AAV) CDMO Market to Reach USD 3.90 Billion by 2035 as Gene Therapy Manufacturing Outsourcing Accelerates – SNS Insider

Growing gene therapy pipelines, rare-disease programs, GMP capacity demand, and increasing reliance on specialized CDMOs are expanding AAV manufacturing opportunities.

Austin, United States, Aug. 13, 2026 (GLOBE NEWSWIRE) — According to SNS Insider, the Adeno-Associated Virus (AAV) CDMO Market was valued at USD 0.61 billion in 2025 and is projected to reach USD 3.90 billion by 2035, registering a CAGR of 20.34% from 2026 to 2035.

The global AAV CDMO market is experiencing robust growth due to increasing demand for outsourced gene therapy manufacturing, expanding rare-disease programs, growing clinical pipelines, advances in AAV manufacturing technologies, and increasing adoption of gene therapies. More than 40 clinical studies with AAV-based gene therapy were carried out worldwide in 2025 based on FDA CBER & EMA data.

Access the AAV CDMO Market Sample Report: https://www.snsinsider.com/sample-request/10506

Key Takeaways:

• Leading Therapeutic Area: Neurology (~39.84% share)
• Leading Service Type: AAV Vector Manufacturing (~56.32% share)
• Leading Vector Type: Self-Complementary AAV (~50.73% share)
• Leading Capacity: Medium-Scale (~50.12% share)
• Leading End User: Large Pharma (~54.76% share)
• Largest Regional Market: North America (~41.86% share)
• Fastest-Growing Regional Market: Asia Pacific (22.48% CAGR)

The report provides decision-making intelligence for companies evaluating AAV CDMO partnerships, manufacturing capacity, competitive positioning, and regional growth opportunities. It covers market size and forecasts, service types, therapeutic areas, vector types, manufacturing capacity, end users, regional trends, and key market players through 2035.

AAV Manufacturing Outsourcing and Gene Therapy Pipeline Expansion Drive Market Growth

The AAVs are increasingly outsourced by the biopharmaceutical industry to dedicated CDMOs owing to the cost associated with the equipment needed for manufacturing the vectors. The CDMOs offer a range of services from clinical to commercial stages, which lead to the efficiency in the process with minimal risks, while collaboration of the biotechnology firms with the foreign CDMOs increases the availability of advanced methods of manufacturing. According to Alliance for Regenerative Medicine, 70% of the gene therapy clinical studies use AAV-mediated strategies.

AAV CDMO Market Segmentation Analysis

AAV CDMO Market by Therapeutic Area

Neurology had the maximum share of 39.84% in 2025, owing to high incidence of neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease as well as increased utilization of gene therapy for central nervous system disorders through outsourcing. Ophthalmology has been the fastest growing market segment with a 26.65% CAGR, owing to increased incidence of inherited retinal disorders and successful retinal gene therapy using AAV vectors.

AAV CDMO Market by Service Type

AAV Vector Manufacturing captured the largest market share at about 56.32% in 2025 owing to its widespread adoption in the field of gene therapy development and commercialization and increasing demand for scale-up and Good Manufacturing Practice (GMP) compliant manufacturing facilities. Lentiviral Vector Manufacturing has been identified as the fastest growing segment at a 23.94% Compound Annual Growth Rate (CAGR).

AAV CDMO Market by Vector Type

Self-Complementary AAV captured the largest market share of almost 50.73%, backed by its effectiveness in delivering genes and rapid gene expression without the need for second-strand DNA synthesis process. In terms of growth rate, Single Stranded AAV vectors have been witnessing the highest growth of 22.82% CAGR during the forecast period due to its ability to carry more genetic material.

AAV CDMO Market by Capacity

The Medium Scale segment was leading with approximately 50.12% share in 2025 due to its suitability regarding maximum scalability, affordability, and flexibility as well as minimal manufacturing risks compared to large-scale segments. The Large-Scale category is the fastest-growing segment with a 24.51% CAGR as a result of commercialization of gene therapy and increase in pharmaceutical spending on scalable manufacturing facilities.

AAV CDMO Market by End User

The Large Pharma segment held market share of about 54.76% in 2025, owing to robust financial capability, existing biologics pipeline, and preference for manufacturing through CDMO partnerships, which are scalable and compliant in nature. The Biotech Start-ups end user segment represents the fastest growing end user segment at CAGR of 23.97%, owing to innovations in rare diseases treatments and outsourcing.

AAV CDMO Market Regional Analysis

The North American market represented approximately 41.86% of the global market share in 2025, owing to robust presence of biopharma companies, efficient biotechnology infrastructure, and huge investment in gene therapy in the region. The growing demand for large-scale production of viral vectors and clinical trials for rare diseases is contributing to increasing outsourcing activities, underpinned by a robust regulatory landscape supporting consistent CDMO adoption.

U.S. AAV CDMO Market

The U.S. Adeno-Associated Virus (AAV) CDMO Market was valued at USD 0.22 billion in 2025 and is expected to reach around USD 1.21 billion by 2035, growing at a CAGR of 18.49% from 2026–2035. The U.S. adeno-associated virus (AAV) CDMO market is growing steadily owing to strong demand for gene therapy manufacturing services. Increasing prevalence of rare genetic diseases is supporting market expansion.

Europe AAV CDMO Market

The Europe Adeno-Associated Virus (AAV) CDMO Market is expected to witness a valuation of USD 0.18 Billion in 2025 and will reach USD 1.09 Billion by 2035, registering a CAGR of approximately 19.69% over the period of 2026-2035. Europe has been witnessing consistent growth, attributable to robust regulatory frameworks along with a well-established biotech industry in countries such as Germany, France, UK, and Switzerland, where demand for novel gene therapies remains consistent.

Asia-Pacific AAV CDMO Market

The Asia-Pacific region is the highest growing region at a CAGR of roughly 22.48%, thanks to the fast-growing biotherapeutics industry and increasing number of clinical trials in the major economies in the region. China, India, Japan, and South Korea are spending significantly on developing gene therapies, and increased manufacturing outsourcing and patient population is boosting growth.

Explore the Complete Adeno-Associated Virus (AAV) CDMO Market Report: https://www.snsinsider.com/reports/adeno-associated-virus-cdmo-market-10506

Leading Market Players Listed in this Report are:

• Lonza
• Thermo Fisher Scientific
• WuXi AppTec
• Fujifilm Diosynth Biotechnologies
• AGC Biologics
• Samsung Biologics
• Charles River Laboratories
• Oxford Biomedica
• Merck KGaA
• Pfizer
• Abzena
• Emergent BioSolutions
• FinVector
• Batavia Biosciences
• Recipharm
• WuXi Biologics
• Boehringer Ingelheim
• Rentschler Biopharma
• Vive Biotech
• Polymun Scientific

Recent Developments:

• 2026: WuXi AppTec increased gene therapy CDMO capacity with new AAV production suites and advanced analytical technology upgrades in China.
• 2025: Lonza expanded viral vector and gene therapy manufacturing capabilities in Switzerland and the U.S. to support growing AAV demand.

Frequently Asked Questions (FAQs):

Q: What is the expected CAGR of the AAV CDMO market from 2026 to 2035?
A: The market is expected to grow at a CAGR of 20.34% from 2026 to 2035.

Q: What was the size of the AAV CDMO market in 2025?
A: The market was valued at USD 0.61 billion in 2025.

Q: What is the major growth factor driving the AAV CDMO market?
A: Rising outsourcing of gene therapy manufacturing to specialized CDMO providers and expanding clinical pipelines are the major growth drivers.

Q: Which service type segment dominated the AAV CDMO market?
A: AAV Vector Manufacturing dominated with around 56.32% share in 2025.

Q: Which region dominated the AAV CDMO market in 2025?
A: North America dominated with around 41.86% of global market share in 2025.

Purchase the Complete AAV CDMO Market Report: https://www.snsinsider.com/checkout/10506

Adeno-Associated Virus (AAV) CDMO Market Report Scope

Recently Published Press Releases

Pet Insurance Market Size To Exceed $101.61 Billion By 2035

Ethylene Oxide Sterilization Services Market Size To Exceed $15.62 Billion By 2035

AI In Animal Health Market Size To Exceed $12.8 Billion By 2035

Clinical Trial Equipment & Ancillary Solutions Market Size To Exceed $5.34 Billion By 2035

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Rohan Jadhav - Principal Consultant Phone: +1-315-961-9094 (US) Email: [email protected] 

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. DailyIndiaNews.com takes no editorial responsibility for the same.